Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.
ADAMTS4 Protein
/ genetics
Adult
Aged
Bile
/ metabolism
Biomarkers, Tumor
/ genetics
Cancer-Associated Fibroblasts
/ metabolism
Cholangiocarcinoma
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Female
Humans
Male
Middle Aged
Neoplasms
/ genetics
Peptides
/ genetics
Proteomics
/ methods
Tumor Microenvironment
/ genetics
Biomarkers
Biomolecular pathways
Cholangiocarcinoma
Proteomics
Journal
Journal of biomedical science
ISSN: 1423-0127
Titre abrégé: J Biomed Sci
Pays: England
ID NLM: 9421567
Informations de publication
Date de publication:
03 Jan 2020
03 Jan 2020
Historique:
received:
09
08
2019
accepted:
10
12
2019
entrez:
5
1
2020
pubmed:
5
1
2020
medline:
6
6
2020
Statut:
epublish
Résumé
Detection of cholangiocarcinoma (CCA) remains a diagnostic challenge. We established diagnostic peptide biomarkers in bile and urine based on capillary electrophoresis coupled to mass spectrometry (CE-MS) to detect both local and systemic changes during CCA progression. In a prospective cohort study we recently demonstrated that combined bile and urine proteome analysis could further improve diagnostic accuracy of CCA diagnosis in patients with unknown biliary strictures. As a continuation of these investigations, the aim of the present study was to investigate the pathophysiological mechanisms behind the molecular determinants reflected by bile and urine peptide biomarkers. Protease mapping and gene ontology cluster analysis were performed for the previously defined CE-MS based biomarkers in bile and urine. For that purpose, bile and urine peptide profiles (from samples both collected at the date of endoscopy) were investigated from a representative cohort of patients with benign (n = 76) or CCA-associated (n = 52) biliary strictures (verified during clinical follow-up). This was supplemented with a literature search for the association of the individual biomarkers included in the proteomic patterns with CCA or cancer progression. For most of the peptide markers, association to CCA has been described in literature. Protease mapping revealed ADAMTS4 activity in cleavage of both bile and urine CCA peptide biomarkers. Furthermore, increased chymase activity in bile points to mast cell activation at the tumor site. Gene ontology cluster analysis indicates cellular response to chemical stimuli and stress response as local and extracellular matrix reorganization by tissue destruction and repair as systemic events. The analysis further supports that the mapped proteases are drivers of local and systemic events. The study supports connection of the CCA-associated peptide biomarkers to the molecular pathophysiology and indicates an involvement in epithelial-to-mesenchymal transition, generation of cancer-associated fibroblasts and activation of residual immune cells. Proteases, extracellular matrix components, inflammatory cytokines, proangiogenic, growth and vasoactive factors released from the tumor microenvironment are drivers of systemic early events during CCA progression.
Sections du résumé
BACKGROUND
BACKGROUND
Detection of cholangiocarcinoma (CCA) remains a diagnostic challenge. We established diagnostic peptide biomarkers in bile and urine based on capillary electrophoresis coupled to mass spectrometry (CE-MS) to detect both local and systemic changes during CCA progression. In a prospective cohort study we recently demonstrated that combined bile and urine proteome analysis could further improve diagnostic accuracy of CCA diagnosis in patients with unknown biliary strictures. As a continuation of these investigations, the aim of the present study was to investigate the pathophysiological mechanisms behind the molecular determinants reflected by bile and urine peptide biomarkers.
METHODS
METHODS
Protease mapping and gene ontology cluster analysis were performed for the previously defined CE-MS based biomarkers in bile and urine. For that purpose, bile and urine peptide profiles (from samples both collected at the date of endoscopy) were investigated from a representative cohort of patients with benign (n = 76) or CCA-associated (n = 52) biliary strictures (verified during clinical follow-up). This was supplemented with a literature search for the association of the individual biomarkers included in the proteomic patterns with CCA or cancer progression.
RESULTS
RESULTS
For most of the peptide markers, association to CCA has been described in literature. Protease mapping revealed ADAMTS4 activity in cleavage of both bile and urine CCA peptide biomarkers. Furthermore, increased chymase activity in bile points to mast cell activation at the tumor site. Gene ontology cluster analysis indicates cellular response to chemical stimuli and stress response as local and extracellular matrix reorganization by tissue destruction and repair as systemic events. The analysis further supports that the mapped proteases are drivers of local and systemic events.
CONCLUSIONS
CONCLUSIONS
The study supports connection of the CCA-associated peptide biomarkers to the molecular pathophysiology and indicates an involvement in epithelial-to-mesenchymal transition, generation of cancer-associated fibroblasts and activation of residual immune cells. Proteases, extracellular matrix components, inflammatory cytokines, proangiogenic, growth and vasoactive factors released from the tumor microenvironment are drivers of systemic early events during CCA progression.
Identifiants
pubmed: 31900160
doi: 10.1186/s12929-019-0599-5
pii: 10.1186/s12929-019-0599-5
pmc: PMC6941325
doi:
Substances chimiques
Biomarkers, Tumor
0
Peptides
0
ADAMTS4 Protein
EC 3.4.24.82
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Références
Cell Mol Immunol. 2014 Jul;11(4):377-86
pubmed: 25000533
J Am Heart Assoc. 2017 Aug 7;6(8):null
pubmed: 28784649
Gastrointest Endosc. 2002 Nov;56(5):720-30
pubmed: 12397282
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Cell Physiol Biochem. 2018;46(4):1693-1703
pubmed: 29694979
J Mol Cell Biol. 2016 Feb 17;:null
pubmed: 26892022
Mol Cell Proteomics. 2010 Nov;9(11):2424-37
pubmed: 20616184
J Gastroenterol Hepatol. 2015 Mar;30(3):600-8
pubmed: 25160604
Nephrol Dial Transplant. 2017 Mar 1;32(3):487-497
pubmed: 27382111
Endoscopy. 2012 Nov;44(11):1055-8
pubmed: 23108773
Endocr Relat Cancer. 2005 Sep;12(3):631-43
pubmed: 16172196
PLoS Genet. 2011 Jun;7(6):e1001393
pubmed: 21695224
Am J Pathol. 2016 Jan;186(1):123-33
pubmed: 26597881
Eur J Surg Oncol. 1998 Feb;24(1):60-7
pubmed: 9542520
Hepatology. 2011 Mar;53(3):875-84
pubmed: 21374660
Clin Gastroenterol Hepatol. 2011 May;9(5):434-9.e1
pubmed: 21334457
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):267-75
pubmed: 25966427
Best Pract Res Clin Gastroenterol. 2011 Dec;25(6):741-52
pubmed: 22117639
J Exp Med. 2018 Mar 5;215(3):827-840
pubmed: 29432122
Lancet Oncol. 2006 Mar;7(3):230-40
pubmed: 16510332
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
J Proteome Res. 2009 Jan;8(1):268-81
pubmed: 19012428
Gut. 2013 Jan;62(1):122-30
pubmed: 22580416
Oncotarget. 2017 Apr 20;8(41):69435-69455
pubmed: 29050215
Hepatology. 2012 Nov;56(5):1792-803
pubmed: 22707408
Sci Rep. 2018 Mar 27;8(1):5227
pubmed: 29588543
J Hepatol. 2000 Dec;33(6):961-6
pubmed: 11131459
Nat Genet. 2009 Feb;41(2):166-7
pubmed: 19169256
Dtsch Arztebl Int. 2013 Dec 23;110(51-52):867-74
pubmed: 24529302
Clin Biochem. 2013 Apr;46(6):432-43
pubmed: 23041249
Mol Cancer. 2015 May 20;14:107
pubmed: 25990935
Mol Med Rep. 2019 Jan;19(1):3-14
pubmed: 30483776
J Chromatogr A. 2003 Sep 26;1013(1-2):173-81
pubmed: 14604118
Nat Rev Immunol. 2013 Sep;13(9):679-92
pubmed: 23954936
Am J Physiol Lung Cell Mol Physiol. 2017 May 1;312(5):L710-L721
pubmed: 28235950
BMC Cancer. 2011 Oct 05;11:427
pubmed: 21975049
Oncol Rep. 2013 Apr;29(4):1259-67
pubmed: 23426976
FEBS Lett. 2009 Dec 17;583(24):3966-73
pubmed: 19850042
Cancer Cell. 2017 Jul 10;32(1):57-70.e3
pubmed: 28648284
Nat Biotechnol. 2008 Jun;26(6):685-94
pubmed: 18500335
Arch Biochem Biophys. 2008 Oct 1;478(1):43-51
pubmed: 18671934
Neoplasia. 2008 Dec;10(12):1481-92, 3p following 1492
pubmed: 19048126
Curr Opin Pharmacol. 2015 Dec;25:45-9
pubmed: 26629596
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2118-2127
pubmed: 28743596
Lancet. 2005 Oct 8;366(9493):1303-14
pubmed: 16214602
Cell Mol Life Sci. 2011 Mar;68(6):965-75
pubmed: 21069421
Crit Rev Clin Lab Sci. 2016 Aug;53(4):277-91
pubmed: 26886390
Sci Rep. 2017 Jan 16;7:40473
pubmed: 28091549
J Hepatol. 2008;48 Suppl 1:S38-57
pubmed: 18304683
J Biol Chem. 2008 Nov 7;283(45):30433-7
pubmed: 18650443
Clin Cancer Res. 2009 Aug 1;15(15):4935-43
pubmed: 19602546
Autoimmun Rev. 2017 Jun;16(6):557-563
pubmed: 28411167
Adv Protein Chem Struct Biol. 2018;110:167-202
pubmed: 29412996
Asian Pac J Cancer Prev. 2011;12(6):1503-10
pubmed: 22126489
Oncotarget. 2016 Sep 27;7(39):62925-62938
pubmed: 26910837
United European Gastroenterol J. 2017 Aug;5(5):668-676
pubmed: 28815030
JAMA Intern Med. 2013 Jul 8;173(13):1222-8
pubmed: 23753274
Genom Data. 2016 Jan 15;7:229-32
pubmed: 26981414
Clin Cancer Res. 2007 May 1;13(9):2584-91
pubmed: 17473187
Eur J Clin Invest. 2019 May;49(5):e13087
pubmed: 30767196
J Biol Chem. 2003 Dec 5;278(49):49145-53
pubmed: 13679373
Nat Genet. 2007 Nov;39(11):1369-75
pubmed: 17952072
BMC Cancer. 2016 Mar 10;16:206
pubmed: 26965049
Proteomics. 2013 Apr;13(7):1077-82
pubmed: 23348921
Clin Cancer Res. 2016 Aug 15;22(16):4077-86
pubmed: 27026199
Nephrol Dial Transplant. 2014 Dec;29(12):2260-8
pubmed: 24981581
Am J Nephrol. 2014;40(5):458-67
pubmed: 25503683
Molecules. 2018 Jan 22;23(1):null
pubmed: 29361765
J Carcinog. 2015 Feb 23;14:1
pubmed: 25788866
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Gastroenterology. 2012 Apr;142(4):1021-1031.e15
pubmed: 22178589
Ann N Y Acad Sci. 2003 Apr;986:382-7
pubmed: 12763854
J Biol Chem. 2004 Jul 23;279(30):31664-70
pubmed: 15123616
Oncogene. 2016 Oct 6;35(40):5263-5271
pubmed: 26996663